After one and a half year on the market, Novo Nordisk's GLP-1-analogue Ozempic generates twice as much revenue as Victoza and Trulicity did in the same period after their launch. Novo Nordisk is "very satisfied" with the results.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.